More importantly, the obtained risk score remained significant (HR = 0.53 95% CI: [0.33–0.86), P-value = 0.01, Figure 4E) even when considered together with relevant clinical parameters for GBM patients, including age at diagnosis, chromosome 19/20 co-gain, G-CIMP, IDH1 mutation and MGMT methylation status. This evidence concerns the gene MGMT and glioblastoma.